All Stories
Follow
Subscribe to Medigene AG

Medigene AG

euro adhoc: MediGene AG
MediGene's First Drug Eligard® Is Launched (E)

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Martinsried - San Diego, May 4, 2004. Eligard®, the first drug of the
German-American biotechnology company MediGene AG (Frankfurt, Prime
Standard: MDG), is available in German pharmacies today. With the
launch of the prescription drug to treat advanced prostate cancer,
MediGene becomes the first German biotech company with a drug on the
market. The Japanese pharmaceuticals group Yamanouchi takes over the
commercialization of Eligard®. Yamanouchi is the second largest
pharmaceuticals company in Europe in the field of urology, and the
market leader in the field of benign hyperplasia. In Germany, more
than 120 medical representatives nationwide will promote Eligard®
with urologists. Upon launch, MediGene receives a milestone payment
from Yamanouchi. In addition, MediGene will receive royalties on
sales of Eligard®.
By the end of this year, marketing authorization applications shall
be submitted for Eligard® in other European countries. MediGene
acquired the license for pan-European commercialization of Eligard®
from the US Company Atrix Laboratories, Inc. in April 2001, and has
successfully taken both the one-month and the three-months products
through the approval procedure. For this purpose, MediGene adapted
the US marketing dossier to the requirements of the German regulatory
authorities and supplemented the clinical data with additional
preclinical studies. MediGene and Yamanouchi also hold the licenses
for the 4-months and 6-months products of Eligard®.
Eligard® is an LH-RH agonist (LH-RH = luteinizing hormone-releasing
hormone) which significantly and consistently reduces the
testosterone level in the body, thus suppressing tumor growth in
patients suffering from advanced, hormone-dependent prostate cancer
(palliative therapy). Liquid Eligard® is injected subcutaneously into
the patient where it forms a solid depot, slowly and steadily
releasing the drug, while the biodegradable depot disintegrates. The
clinical trials have shown that Eligard® is safe, well tolerated and
efficient.
Contact
MediGene AG 
Email:  	investor@medigene.com 
Fax:	++49 - 89 - 85 65- 2920
Julia Hofmann, Public Relations
Tel.: 	++49 - 89 - 85 65- 3324
Dr. Michael Nettersheim, Investor Relations
Tel.: 	++49 - 89 - 85 65- 2946
end of announcement        euro adhoc 04.05.2004

Further inquiry note:

Julia Hofmann
Tel.: +49 (0)89 8565 3324
E-mail: j.hofmann@medigene.com

Branche: Biotechnology
ISIN: DE0005020903
WKN: 502090
Index: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Niedersächsische Börse zu Hannover / free trade
Berliner Wertpapierbörse / free trade
Bayerische Börse / free trade
Hamburger Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade

Original content of: Medigene AG, transmitted by news aktuell

More stories: Medigene AG
More stories: Medigene AG